Drug Device Combination Market to 2016 - Technological Convergence to be the New Business Model for Growth and Profitability - GBI Research Reports

Drug Device Combination Market to 2016 - Technological Convergence to be the New Business Model for Growth and Profitability

Drug Device Combination Market to 2016 - Technological Convergence to be the New Business Model for Growth and Profitability - GBI Research Reports
Drug Device Combination Market to 2016 - Technological Convergence to be the New Business Model for Growth and Profitability
Published Jan 31, 2011
95 pages — Published Jan 31, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Researchs medical devices report, Drug Device Combination Market to 2016 -Technological Convergence to be the New Business Model for Growth and Profitability provides key data, information and analysis on the global drgu-device combination market. The report provides market landscape, competitive landscape and market trends information on six dental devices market categories Drug eluting stents, antimicrobial catheters, antibiotic-loaded bone cements, drug-eluting beads, photodynamic therapy. The report provides comprehensive information on the key trends affecting these categories, and key analytical content on the market dynamics. The report also reviews the competitive landscape, key pipeline products and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

Scope

- Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
- Market size and company share data for the drug-device combination market categories Drug eluting stents, antimicrobial catheters, antibiotic-loaded bone cements, drug-eluting beads, photodynamic therapy
- Annualized market revenues data from 2002 to 2009, forecast forward for 7 years to 2016. Company shares data for 2009.
- Qualitative analysis of key market trends, market drivers, and restraints by each category within the drug-device combination market.
- The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.

Reasons to buy

- Develop business strategies by understanding the trends and developments that are driving the drug-device combination market globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Identify key players best positioned to take advantage of the emerging market opportunities.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Whats the next being thing in the drug-device combination market landscape? Identify, understand and capitalize.
- Make more informed business decisions from the insightful and in-depth analysis of the global drug-device combination market and the factors shaping it.

  
Source:
Document ID
GBIME0015MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents36
  List of Tables71
  List of Figures81
Introduction91
  GBI Research Guidance91
Overview106
  Introduction to Drug/Device Combination Products101
  Commercialization Cycle of a Drug/Device CP111
    Categorization111
      The PMOA rule111
      A Request for Designation (RFD)111
      Device and Drug Classification121
      Clinical Investigation121
      Pre-Market Approval (PMA)131
      Product Approval for Marketing131
  Drug/Device CP: Applications141
  Drug/Device CP: Products141
  Research Scope151
Drug/Device CP Market Characterization1612
  Global Drug/Device CP Market161
    Historical Revenues161
    Market Forecasts171
  Key Market Trends181
    Large Volumes of Research &Development are Expected to Bring Forth Several New Product Launches181
    Cross-Disciplinary Alliances are Becoming Inevitable191
    Geographical Organic and Inorganic Expansion into APAC and Other Developing Nations is Bound to Spurt Growth191
  Technology Trends201
    Design and Development Technologies are Maturating201
    Large Numbers of New Product Developments are Undertaken to Stay in the Race201
    Shifting of Healthcare Provision Modes from Treatment in a Hospital Setting to Disease Prevention and Home Based Care201
    Changes in Design Concepts have Emerged from Alliances Between Drugs and Devices Industries201
  Market Drivers211
    Advances in Technology are Driving Growth of the Drug/Device CP Market211
    Rising Awareness among the Stakeholders Accelerates Market Growth211
    The Combination Products Promise to Avoid Systemic Effects and Toxicity and increases Efficacy of Therapy221
    Reviving of failed pharmaceutical products Lowers Development Time and Costs to Launch Newer CPs221
    Greater positive effects than the medical device operating alone221
    Regulatory processes are gaining clarity worldwide to invite bigger market participation231
    Rising Medical insurance coverage in increasing Clinical Adoption Rates231
    Broadening Range of Applications for Drug/Device CPs will increase Market Volumes Aggressively231
    A Competitive Pressure to Achieve Corporate Goals Lure Medical Device Companies into this Space231
  Market Restraints241
    Several Jurisdiction Issues Deter Market Growth Considerably241
    A Changing Regulatory Environment Creates Confusion and Lack of Clarity among Participants241
    Patient Compliance for these Products has Lowered Slightly, and is Affecting Adoption Rates241
    The relatively High Investment Costs in the Market Curtails Market Growth Considerably241
  Market Challenges251
    Cross-Industry Partnership Issues is a Major Challenge to Market Growth251
    Non-standard PMOA determination processes is a noteworthy lacunae in the regulatory processes261
    Several Major Business Risks Exist Within this Industry261
    Technology Issues Result in Large Development Timelines and Market Slow-down261
  Key Opportunity Areas271
    Addressing Legal and Regulatory Challenges Will Enlighten Dark Areas within The System And Enable Easy Transgression Through The Regulatory Cycles271
    Improving Finance Attracting Ability of Emerging Research-Oriented Bio-Tech Companies Will Aid in Promoting R&D271
    Expanding Product Portfolio Using Existing Knowledge Base Will Enable Easier Market Entry and Expansion271
    Increasing Product Accessibility to All Geographies With Unmet Demands Will Increase Sales Volumes For The Key Market Players271
Drug/Device CP Market: Segment Analysis And Forecasts2824
  Drug-Eluting Stents281
    Segment Overview281
      Foreground281
      DES design281
      Development of the DES Market281
      Pipeline DES products:291
    Market Forecasts291
    Market Drivers301
      Advantages over BMS301
      Next- generation DES301
      2-G DES Have Transformed the Interventional Cardiology Market311
      Greater Prevalence of the High-Risk Group311
      Greater Medical Reimbursement for DES Applications311
    Market Restraints311
      Undesired implications of the DAPT therapy311
      Adverse Effects Post-Surgery Restrict Market Growth311
      Preventive Measures for Occurrence of Coronary Disorders311
      Cost Consideration among DES and BMS Stents311
      Stiff Competition from Advanced Technologies321
    Market Opportunities321
      New generation DES reducing risk of late in-stent thrombosis321
      Research and Development321
      Demonstrating efficient cost effectiveness321
  Antimicrobial Catheters331
    Segment Overview331
      Catheter-related Infection331
      Development of Anti-microbial Catheters331
    Market Forecasts341
    Market Drivers351
      Lowered Hospitalization Costs351
      Rising Awareness351
      Greater prevalence of cardiac disorders, UTI that require surgical procedures351
      Stricter Regulations Worldwide351
    Market Restraints351
      Price constraints351
      Co-morbidities351
      Controversial Development of Drug Resistance351
      Absence of a Good Antibiotic Pipeline361
      Poor Quality of Available Data361
    Market Opportunities361
      Increasing Awareness of Physicians and Surgeons361
      Resolving reimbursement issues361
  Antibiotic-Loaded Bone Cements371
    Segment Overview371
      Introduction371
      Development of ALBC371
      Performance characteristics of ALBCs371
      Clinical Applications381
    Market Forecasts391
    Market Drivers401
      Effective Infection Control because of Localized Treatment401
      Decreased Healthcare Cost Burden401
      Greater life-expectancy401
      Drawbacks of Handmade Antibiotic Coatings on Bone Cements401
      Technological Advancements401
    Market Restraints411
      Antibiotic and its Dosage as per Chosen Product411
      Decreased Bacterial Resistance411
      Costlier Treatment lowers Market Adoption Considerably411
      Decreased Mechanical Strength of the Cement411
  Drug Eluting Beads (DEB)421
    Segment Overview421
      The Drug-eluting beads (DEB) technology platform421
      DEB in the treatment of cancer: Embolization therapy421
      Drug-Eluting Beads breakthrough studies:421
    Market Forecasts431
    Market Drivers441
      Advantages over conventional TACE441
      High prevalence of HCC in Asia and CRC in China/Japan441
      Organic Expansion Plans441
      Clinical Trial completion441
      Increasing Medical Insurance Coverage441
    Market Restraints441
      Scarce skilled resources and expensive DEB cancer therapy:441
      Occurrence of PES (post-embolization syndrome)441
      Lengthy procedural volumes in to make therapeutic procedures available for clinical usage451
  Photodynamic Therapy451
    Segment Overview451
      Introduction to the PDT Process451
      The three mechanisms of damaging the tumor cells461
      Treatable cancers:471
      Research and Development471
      Photosensitizing Agents471
      The three main classes of Photosensitizing Agents used are:471
      Clinically approved Photosensitizers:481
      Light Delivery:481
      Pipeline PDT Products:491
    Market Forecasts491
    Market Drivers501
      Localized treatment increases efficacy of the therapy501
      Treatment using PDT is patient friendly, clinically and economically501
      Application of one drug for multiple therapies501
      Limited Side effects and Additional Benefits lure Patients and Increase Adoption Rates501
      Technological Advancements501
    Market Restraints511
      Competition from Traditional Treatments511
      Clinical Issues511
      Procedure Repetition511
      Limited Applications511
      Limited Market Potential511
    Market Opportunities511
Drug/Device CP Market: Geographical Analysis and Forecasts524
  The US Market522
  The European Union (EU) Market541
  The Rest-of-World (ROW) Market542
Drug/Device CP Market: Regulatory Issues5615
  Introduction561
  Common Regulatory Issues571
    Compliance Issues571
    Pre-Clinical Testing Issues571
    Sterilization Issues581
    Safety and Efficacy Issues581
    Good Manufacturing Practices (GMP) Issues581
    Packaging Issues581
    CMC Issues591
    Stability Issues591
    Patent Analysis and IPR Issues601
    Post_Market Surveillance601
    Incident Reporting601
    Adverse Event Reporting611
    Risk Management Issues611
    Reimbursement Issues611
  The FDA and the Office of the Combination Products (OCP)622
  The European Medical Device Directive (MDD)641
    Mode of Action (MOA)643
  Japanese Regulatory Approach: The MHLW671
    Drugs671
    Medical devices671
    CP Jurisdiction671
  The Australian Therapeutic Goods Administration (TGA) and the Office of Devices, Blood and Tissues (ODBT)681
    TGA Framework681
    Key Challenges faced under the TGA by CP Manufacturers691
  State Food and Drug Administration (SFDA) and the Regulatory Framework in China691
  International Standards for Drugs and Devices701
Drug/Device CP Market: Competitive Landscape7117
  DES Market711
    Key Industry Participants711
    Key Company Profiles721
      Abbott Vascular721
      Medtronic, Inc.721
      Boston Scientific Corporation721
      Company Market Shares731
      Key Product Portfolios741
      Some other DES that have received clinical approval751
      DES in Development Stage751
  Antimicrobial Catheters761
    Key Industry Participants761
    Key Company Portfolios761
      Teleflex Medical (Arrow International)761
      Rochester Medical Corporation761
    Company Market Shares771
    Key Product Portfolios771
      Antimicrobial Catheter Concepts772
  Antibiotic Loaded Bone Cement791
    Key Industry Participants791
    Key Company Portfolios791
      DePuy Orthopaedics (Johnson and Johnson)791
      Biomet, Inc.791
      Zimmer Holdings, Inc.791
    Company Market Shares801
    Key Product Portfolios811
  Drug- Eluting Beads821
    Key Industry Participants821
    Key Company Portfolios821
      Biocompatibles International plc821
      BioSphere Medical, Inc. (Merit Medical Systems)821
      Sirtex Medical Europe GmbH831
    Company Market Shares831
    Key Product Portfolios841
      DC Bead841
      LC Bead841
      Bead Block841
      SIR-Spheres841
  Photodynamic Therapy851
    Key Industry Participants851
    Key Company Portfolios851
      DUSA Pharmaceuticals851
      QLT, Inc.:851
      Rofin Australia:851
    Company Market Shares861
    Key Product Portfolios861
      Visudyne861
      Omnilux861
      Levulan Kerastick871
Drug/Device CP Market: Strategic Consolidation883
  Mergers &Acquisitions (M&A)881
  Licensing &Partnerships881
    Other notable alliances:891
    Existing Alliances:891
  Future Outlook901
Appendix915
  Abbreviations912
  Definitions931

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Drug Device Combination Market to 2016 - Technological Convergence to be the New Business Model for Growth and Profitability" Jan 31, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Drug-Device-Combination-Market-to-2016-Technological-Convergence-to-be-the-New-Business-Model-for-Growth-and-Profitability-2115-167>
  
APA:
GBI Research Reports. (2011). Drug Device Combination Market to 2016 - Technological Convergence to be the New Business Model for Growth and Profitability Jan 31, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Drug-Device-Combination-Market-to-2016-Technological-Convergence-to-be-the-New-Business-Model-for-Growth-and-Profitability-2115-167>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.